NCT06092047 - UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

April 30, 2028

Conditions

CD19-positive Relapsed or Refractory B-cell Malignancies

Interventions

BIOLOGICAL

UTAA09 cells for infusion

Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.

DRUG

Fludarabine

30 mg/m\^2/day×4 days

DRUG

Cyclophosphamide

1000 mg/m\^2/day×3 days

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of USTC (AnHui Provincial Hospital), Hefei